Next Article in Journal
Macrophages and Immune Responses in Uterine Fibroids
Previous Article in Journal
Metabolic Signatures in Coronary Artery Disease: Results from the BioHEART-CT Study
Previous Article in Special Issue
A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts
 
 
Review

Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells

1
UMR-S 1172—LilNCog—Lille Neuroscience & Cognition, Université de Lille, Inserm, CHU Lille, F-59000 Lille, France
2
Neurology and Movement Disorders Department, CHU Lille University Hospital, F-59000 Lille, France
*
Authors to whom correspondence should be addressed.
Academic Editor: Michele Morari
Cells 2021, 10(5), 981; https://doi.org/10.3390/cells10050981
Received: 17 March 2021 / Revised: 15 April 2021 / Accepted: 16 April 2021 / Published: 22 April 2021
(This article belongs to the Collection LRRK2-Dependent Neurodegeneration in Parkinson’s Disease)
Mutations in the Parkinson’s disease (PD) protein Leucine Rich Repeat Kinase 2 (LRRK2) have been under study for more than 15 years and our understanding of the cellular phenotypes for the pathogenic mutant forms of LRRK2 has significantly advanced. In parallel to research on LRRK2 mutations in experimental systems, clinical characterization of patients carrying LRRK2 mutations has advanced, as has the analysis of cells that are derived from these patients, including fibroblasts, blood-derived cells, or cells rendered pluripotent. Under the hypothesis that patient clinical phenotypes are a consequence of a cascade of underlying molecular mechanisms gone astray, we currently have a unique opportunity to compare findings from patients and patient-derived cells to ask the question of whether the clinical phenotype of LRRK2 Parkinson’s disease and cellular phenotypes of LRRK2 patient-derived cells may be mutually informative. In this review, we aim to summarize the available information on phenotypes of LRRK2 mutations in the clinic, in patient-derived cells, and in experimental models in order to better understand the relationship between the three at the molecular and cellular levels and identify trends and gaps in correlating the data. View Full-Text
Keywords: LRRK2; Parkinson’s disease; phenotypes; neurodegenerative disease; physiopathology; pathogenic mutants LRRK2; Parkinson’s disease; phenotypes; neurodegenerative disease; physiopathology; pathogenic mutants
Show Figures

Figure 1

MDPI and ACS Style

Goveas, L.; Mutez, E.; Chartier-Harlin, M.-C.; Taymans, J.-M. Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells. Cells 2021, 10, 981. https://doi.org/10.3390/cells10050981

AMA Style

Goveas L, Mutez E, Chartier-Harlin M-C, Taymans J-M. Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells. Cells. 2021; 10(5):981. https://doi.org/10.3390/cells10050981

Chicago/Turabian Style

Goveas, Liesel, Eugénie Mutez, Marie-Christine Chartier-Harlin, and Jean-Marc Taymans. 2021. "Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells" Cells 10, no. 5: 981. https://doi.org/10.3390/cells10050981

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop